Familial Chylomicronemia Syndrome Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Significant Surge in Awareness and Diagnosis of this Rare Genetic Disorder
   3. Market Restraints
      1. Limited Patient Pool
      2. High Treatment Costs
   4. Market Opportunity
      1. Greater Awareness, Advancements in Precision Medicine, and a Soaring Emphasis on Rare Disease Research
   5. Market Trends
      1. Increasing Research Collaborations
5. MARKET SEGMENTATION
   1. By Drugs
      1. Glybera
      2. Volanesorsen
   2. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Arrowhead Pharmaceuticals
      2. Akcea Therapeutics
      3. Ionis Pharmaceuticals Inc.
      4. Novartis Pharmaceuticals
      5. UniQure Biopharma B.V.

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Familial Chylomicronemia Syndrome market?

The global market of Familial Chylomicronemia Syndrome is projected to reach USD 35.3 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Familial Chylomicronemia Syndrome market?

The global Familial Chylomicronemia Syndrome market has an estimated annual growth rate of 7.6%.

Q.3. What are the recent trends of Familial Chylomicronemia Syndrome market?

Increasing research collaborationsis one of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Familial Chylomicronemia Syndrome?

The major companies profiled in this report include Arrowhead Pharmaceuticals, Akcea Therapeutics, Ionis Pharmaceuticals Inc., Novartis Pharmaceuticals, UniQure Biopharma B.V.among others.

Q.5. Which is the largest regional market in the Familial Chylomicronemia Syndrome?

North America is the largest regional market for Familial Chylomicronemia Syndrome.